DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?

Alicja Krejner-Bienias; Katarzyna Grzela; Tomasz Grzela

doi:10.1007/s00005-020-00602-5

DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?

Arch Immunol Ther Exp (Warsz). 2021 Feb 2;69(1):1. doi: 10.1007/s00005-020-00602-5.

Authors

Alicja Krejner-Bienias¹, Katarzyna Grzela², Tomasz Grzela³

Affiliations

¹ Department of Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004, Warsaw, Poland.
² Department of Pediatric Pulmonology and Allergy, Medical University of Warsaw, Warsaw, Poland.
³ Department of Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004, Warsaw, Poland. tomasz.grzela@wum.edu.pl.

Abstract

A novel coronavirus disease, COVID-19, has emerged as a global public health issue. Clinical course of disease significantly correlates with the occurrence of some comorbidities, among them type 2 diabetes. According to recent structural studies the dipeptidyl peptidase 4, a key molecule in the pathophysiology of diabetes, may influence the course of COVID-19. Since DPP4 inhibitors, gliptins, are widely used in diabetes patients, the exact role of DPP4 modulation in SARS-CoV-2 infection, at least in that group, urgently needs to be clarified. In this short review, we discuss this issue with more detail.

Keywords: COVID-19; DPP4; Diabetes; Gliptins; SARS-CoV-2.

Publication types

Review

MeSH terms

Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use*
COVID-19 / complications
COVID-19 / enzymology
COVID-19 / metabolism
COVID-19 Drug Treatment*
Diabetes Mellitus, Type 2 / complications*
Dipeptidyl Peptidase 4 / metabolism*
Dipeptidyl-Peptidase IV Inhibitors / pharmacology
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
Humans
SARS-CoV-2 / drug effects*

Substances

Antiviral Agents
Dipeptidyl-Peptidase IV Inhibitors
DPP4 protein, human
Dipeptidyl Peptidase 4